Here is the rundown on market activity for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). CEO & Chief Science Officer Jack Y. Zhang sold 444,199 shares at an average price of $21.05 on Tue the 20th. That brings the CEO & Chief Science Officer’s holdings to $15,836,357 as reported to the SEC. Director Floyd F. Petersen let go of 3,000 shares at an average price of $19.05 on September 8th. That brings Petersen’s holdings to $1,149,039 per an SEC filing yesterday.
Howard Lee, Director let go of $194,955 worth of shares at an average price of $18.78 on Thu the 1st. The Director now owns $2,150,817 of the stock as recorded in a recent Form 4 SEC filing.
Here are a few additional firms who have increased or decreased their stake in (AMPH). Schwab Charles Investment Management Inc added to its ownership by buying 19,767 shares an increase of 37.2% from 12/31/2015 to 06/30/2016. Schwab Charles Investment Management Inc owns 72,893 shares with a value of $1,176,000. The total value of its holdings increased 55.6%. As of quarter end Numeric Investors LLC had bought 15,000 shares growing its stake by 65.6%. The value of the investment in Amphastar Pharmaceuticals, Inc. went from $275,000 to $611,000 increasing 122.2% for the reporting period.
As of the end of the quarter Metropolitan Life Insurance Co/ny had acquired a total of 2,637 shares growing its holdings by 11.1%. The value of the company’s investment in Amphastar Pharmaceuticals, Inc. increased from $284,000 to $424,000 a change of $140,000 quarter to quarter. As of the end of the quarter Two Sigma Investments, Lp had acquired a total of 18,612 shares growing its position 16.0%. The value of the investment in AMPH went from $1,394,000 to $2,172,000 a change of 55.8% quarter over quarter.
Equity analyst BMO Capital released its first research report on the stock with an initial rating of “Market Perform”. On February 19 analysts at Wells Fargo started coverage giving it an initial rating of “Outperform”.
On January 19 Jefferies made no change to the stock rating of “Buy” but lowered the price target from $18.00 to $17.00. November 13 investment analysts at Jefferies left the stock rating at “Buy” and moved up the price target to $19.00 from $18.00.
On June 3, 2015 Raymond James initiated coverage on the stock setting a rating of “Strong Buy” and price target of $23.00. On March 25 Jefferies kept the stock rating at “Buy” but raised the price expectation to $18.00 from $15.00.
The company is up by 1.69% since yesterday’s close of $19.58. Company chares are trading at $19.91 marginally over the 50 day moving average of $19.01 and which is slightly above the 200 day moving average of $15.61. The 50 day moving average was up $0.90 whereas the 200 day average was up by +27.55%.
The company currently has a P/E ratio of 64.64 and the market value is 898.36M. Investors are a little more bearish on Amphastar Pharmaceuticals, Inc. of late at least if you consider the change in short interest. The firm realized a rise in short interest from August 31, 2016 to September 15, 2016 of 0.08%. Short interest increased 134,205 over that timeframe. With short interest at 1,858,106 and short average daily volume at 367,180, days to cover is 5.1 and the percentage of shorted shares is 0.04% as of September 15.